The broad-spectrum antiparasitic ivermectin against COVID-19 | ||||
| Kasr Al Ainy Medical Journal | ||||
| Volume 26, Issue 2, December 2020 PDF (174.04 K) | ||||
| DOI: 10.4103/kamj.kamj_37_20 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Nadia A. El Dib; Mona I. Ali | ||||
| Abstract | ||||
| Ivermectin, the FDA-approved broad-spectrum antiparasitic drug, has recently shown excellent antiviral effects against many viral infections. This effect was especially important in the current pandemic infection of COVID-19. There are reports that ivermectin inhibited the replication of the virus in 48 h. Studies have been done on other viral infections and on this virus and . The results showed that it affects the viral replication by its effect on the protein transfer between the cytoplasm and nucleus inside the host cells. More information is still needed to approve its use in the treatment and prevention of COVID-19 pandemic, which will necessitate more studies to adjust the dose and mode of administration. | ||||
| Keywords | ||||
| COVID-19; SARS-CoV-2; importin; Ivermectin; RNA viruses; viral inhibition; viral replication | ||||
|
Statistics Article View: 16 PDF Download: 17 |
||||
